Skip to main content
NCBI home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 2003 Feb;95(2):137–144.

Atypical psychotropic medications and their adverse effects: a review for the African-American primary care physician.

Rahn Kennedy Bailey 1
PMCID: PMC2594447  PMID: 12760609

Abstract

There are now five new-generation atypical psychiatric medications currently available. As these new treatments have become more common, they have grown to account for a significant percentage of all psychiatric medications prescribed. This is because of their efficacy in the treatment of several psychiatric disorders, ease of administration, and absence of the well-known extrapyramidal adverse effects long-attributed to the standard dopamine blocking anti-psychotic medications. As these medications have become treatments of choice, we have discovered additional information about their respective side effects. Issues such as bone marrow suppression, endocrine abnormalities, and most recently cardiac arrhythmia have produced concern. This paper will address all in an attempt to inform the primary care physician of the most prominent and clinically relevant adverse effects of these agents. A particular focus will address the increasing concern that these new medications can produce hyperglycemia and diabetes mellitus.

Full text

PDF
137

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahnve S. Correction of the QT interval for heart rate: review of different formulas and the use of Bazett's formula in myocardial infarction. Am Heart J. 1985 Mar;109(3 Pt 1):568–574. doi: 10.1016/0002-8703(85)90564-2. [DOI] [PubMed] [Google Scholar]
  2. Allison D. B., Fontaine K. R., Heo M., Mentore J. L., Cappelleri J. C., Chandler L. P., Weiden P. J., Cheskin L. J. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry. 1999 Apr;60(4):215–220. doi: 10.4088/jcp.v60n0402. [DOI] [PubMed] [Google Scholar]
  3. Allison D. B., Mentore J. L., Heo M., Chandler L. P., Cappelleri J. C., Infante M. C., Weiden P. J. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999 Nov;156(11):1686–1696. doi: 10.1176/ajp.156.11.1686. [DOI] [PubMed] [Google Scholar]
  4. Allison D. B., Mentore J. L., Heo M., Chandler L. P., Cappelleri J. C., Infante M. C., Weiden P. J. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999 Nov;156(11):1686–1696. doi: 10.1176/ajp.156.11.1686. [DOI] [PubMed] [Google Scholar]
  5. Atkin K., Kendall F., Gould D., Freeman H., Liberman J., O'Sullivan D. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry. 1996 Oct;169(4):483–488. doi: 10.1192/bjp.169.4.483. [DOI] [PubMed] [Google Scholar]
  6. CHARATAN F. B., BARTLETT N. G. The effect of chlorpromazine (largactil) on glucose tolerance. J Ment Sci. 1955 Apr;101(423):351–353. doi: 10.1192/bjp.101.423.351. [DOI] [PubMed] [Google Scholar]
  7. Casey D. E. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology (Berl) 1989;99 (Suppl):S47–S53. doi: 10.1007/BF00442559. [DOI] [PubMed] [Google Scholar]
  8. Casey D. E., Keepers G. A. Neuroleptic side effects: acute extrapyramidal syndromes and tardive dyskinesia. Psychopharmacol Ser. 1988;5:74–93. doi: 10.1007/978-3-642-73280-5_7. [DOI] [PubMed] [Google Scholar]
  9. Chakos M., Lieberman J., Hoffman E., Bradford D., Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry. 2001 Apr;158(4):518–526. doi: 10.1176/appi.ajp.158.4.518. [DOI] [PubMed] [Google Scholar]
  10. Dixon L., Weiden P., Delahanty J., Goldberg R., Postrado L., Lucksted A., Lehman A. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull. 2000;26(4):903–912. doi: 10.1093/oxfordjournals.schbul.a033504. [DOI] [PubMed] [Google Scholar]
  11. Floris M., Lejeune J., Deberdt W. Effect of amantadine on weight gain during olanzapine treatment. Eur Neuropsychopharmacol. 2001 Apr;11(2):181–182. doi: 10.1016/s0924-977x(01)00072-4. [DOI] [PubMed] [Google Scholar]
  12. Ghaemi S. N., Sachs G. S., Baldassano C. F., Truman C. J. Acute treatment of bipolar disorder with adjunctive risperidone in outpatients. Can J Psychiatry. 1997 Mar;42(2):196–199. doi: 10.1177/070674379704200211. [DOI] [PubMed] [Google Scholar]
  13. Glazer W. M. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry. 2000;61 (Suppl 3):16–21. [PubMed] [Google Scholar]
  14. Harris M. I., Flegal K. M., Cowie C. C., Eberhardt M. S., Goldstein D. E., Little R. R., Wiedmeyer H. M., Byrd-Holt D. D. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998 Apr;21(4):518–524. doi: 10.2337/diacare.21.4.518. [DOI] [PubMed] [Google Scholar]
  15. Heisler L. K., Chu H. M., Tecott L. H. Epilepsy and obesity in serotonin 5-HT2C receptor mutant mice. Ann N Y Acad Sci. 1998 Dec 15;861:74–78. doi: 10.1111/j.1749-6632.1998.tb10175.x. [DOI] [PubMed] [Google Scholar]
  16. Henderson D. C., Cagliero E., Gray C., Nasrallah R. A., Hayden D. L., Schoenfeld D. A., Goff D. C. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry. 2000 Jun;157(6):975–981. doi: 10.1176/appi.ajp.157.6.975. [DOI] [PubMed] [Google Scholar]
  17. Hummer M., Kemmler G., Kurz M., Kurzthaler I., Oberbauer H., Fleischhacker W. W. Weight gain induced by clozapine. Eur Neuropsychopharmacol. 1995 Dec;5(4):437–440. doi: 10.1016/0924-977x(95)00012-e. [DOI] [PubMed] [Google Scholar]
  18. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988 Sep;45(9):789–796. doi: 10.1001/archpsyc.1988.01800330013001. [DOI] [PubMed] [Google Scholar]
  19. Kapur S., Zipursky R. B., Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999 Feb;156(2):286–293. doi: 10.1176/ajp.156.2.286. [DOI] [PubMed] [Google Scholar]
  20. Kapur S., Zipursky R., Jones C., Remington G., Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000 Apr;157(4):514–520. doi: 10.1176/appi.ajp.157.4.514. [DOI] [PubMed] [Google Scholar]
  21. Katz I. R., Jeste D. V., Mintzer J. E., Clyde C., Napolitano J., Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry. 1999 Feb;60(2):107–115. doi: 10.4088/jcp.v60n0207. [DOI] [PubMed] [Google Scholar]
  22. Kinon B. J., Basson B. R., Gilmore J. A., Tollefson G. D. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry. 2001 Feb;62(2):92–100. [PubMed] [Google Scholar]
  23. Kraemer H. C., Stice E., Kazdin A., Offord D., Kupfer D. How do risk factors work together? Mediators, moderators, and independent, overlapping, and proxy risk factors. Am J Psychiatry. 2001 Jun;158(6):848–856. doi: 10.1176/appi.ajp.158.6.848. [DOI] [PubMed] [Google Scholar]
  24. Krakowski M. I., Kunz M., Czobor P., Volavka J. Long-term high-dose neuroleptic treatment: who gets it and why? Hosp Community Psychiatry. 1993 Jul;44(7):640–644. doi: 10.1176/ps.44.7.640. [DOI] [PubMed] [Google Scholar]
  25. Lavid N., Franklin D. L., Maguire G. A. Management of child and adolescent stuttering with olanzapine: three case reports. Ann Clin Psychiatry. 1999 Dec;11(4):233–236. doi: 10.1023/a:1022365513865. [DOI] [PubMed] [Google Scholar]
  26. Littrell K. H., Petty R. G., Hilligoss N. M., Peabody C. D., Johnson C. G. Olanzapine treatment for patients with schizophrenia and substance abuse. J Subst Abuse Treat. 2001 Dec;21(4):217–221. doi: 10.1016/s0740-5472(01)00205-7. [DOI] [PubMed] [Google Scholar]
  27. Maguire G. A., Riley G. D., Franklin D. L., Gottschalk L. A. Risperidone for the treatment of stuttering. J Clin Psychopharmacol. 2000 Aug;20(4):479–482. doi: 10.1097/00004714-200008000-00013. [DOI] [PubMed] [Google Scholar]
  28. McIntyre R. S., McCann S. M., Kennedy S. H. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry. 2001 Apr;46(3):273–281. doi: 10.1177/070674370104600308. [DOI] [PubMed] [Google Scholar]
  29. McKee H. A., D'Arcy P. F., Wilson P. J. Diabetes and schizophrenia--a preliminary study. J Clin Hosp Pharm. 1986 Aug;11(4):297–299. doi: 10.1111/j.1365-2710.1986.tb00855.x. [DOI] [PubMed] [Google Scholar]
  30. Melkersson K. I., Hulting A. L., Brismar K. E. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry. 2000 Oct;61(10):742–749. doi: 10.4088/jcp.v61n1006. [DOI] [PubMed] [Google Scholar]
  31. Meltzer H. Y. Outcome in schizophrenia: beyond symptom reduction. J Clin Psychiatry. 1999;60 (Suppl 3):3–8. [PubMed] [Google Scholar]
  32. Mokdad A. H., Bowman B. A., Ford E. S., Vinicor F., Marks J. S., Koplan J. P. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001 Sep 12;286(10):1195–1200. doi: 10.1001/jama.286.10.1195. [DOI] [PubMed] [Google Scholar]
  33. Mukherjee S., Decina P., Bocola V., Saraceni F., Scapicchio P. L. Diabetes mellitus in schizophrenic patients. Compr Psychiatry. 1996 Jan-Feb;37(1):68–73. doi: 10.1016/s0010-440x(96)90054-1. [DOI] [PubMed] [Google Scholar]
  34. Perry P. J., Miller D. D., Arndt S. V., Cadoret R. J. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry. 1991 Feb;148(2):231–235. doi: 10.1176/ajp.148.2.231. [DOI] [PubMed] [Google Scholar]
  35. Potkin S. G., Bera R., Gulasekaram B., Costa J., Hayes S., Jin Y., Richmond G., Carreon D., Sitanggan K., Gerber B. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry. 1994 Sep;55 (Suppl B):133–136. [PubMed] [Google Scholar]
  36. Rockwell W. J., Ellinwood E. H., Jr, Trader D. W. Psychotropic drugs promoting weight gain: health risks and treatment implications. South Med J. 1983 Nov;76(11):1407–1412. doi: 10.1097/00007611-198311000-00021. [DOI] [PubMed] [Google Scholar]
  37. Seeman P., Tallerico T. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry. 1998 Mar;3(2):123–134. doi: 10.1038/sj.mp.4000336. [DOI] [PubMed] [Google Scholar]
  38. Shelton R. C., Tollefson G. D., Tohen M., Stahl S., Gannon K. S., Jacobs T. G., Buras W. R., Bymaster F. P., Zhang W., Spencer K. A. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001 Jan;158(1):131–134. doi: 10.1176/appi.ajp.158.1.131. [DOI] [PubMed] [Google Scholar]
  39. Tohen M., Sanger T. M., McElroy S. L., Tollefson G. D., Chengappa K. N., Daniel D. G., Petty F., Centorrino F., Wang R., Grundy S. L. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry. 1999 May;156(5):702–709. doi: 10.1176/ajp.156.5.702. [DOI] [PubMed] [Google Scholar]
  40. Wirshing D. A. Adverse effects of atypical antipsychotics. J Clin Psychiatry. 2001;62 (Suppl 21):7–10. [PubMed] [Google Scholar]
  41. Wirshing D. A., Wirshing W. C., Kysar L., Berisford M. A., Goldstein D., Pashdag J., Mintz J., Marder S. R. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry. 1999 Jun;60(6):358–363. [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES